Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Tesamorelin (trade name Egrifta, Theratechnologies) received FDA approval in November 2010 for the reduction of excess abdominal fat (lipodystrophy) in HIV patients undergoing antiretroviral therapy
Your risk for getting low blood sugar may be higher if you use Tirzepatide with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin
Obesity, insulin resistance, and chronic hyperglycaemia are all associated with increased inflammation and oxidative stress, which can negatively impact brain function
The increase from 10 mg to 15 mg yields more modest incremental benefit
US$ 22.31
US$ 20.93
US$ 24.91
